SCHEMBL6530231

SCHEMBL6530231

Nc1ncnc(-c2cccnc2Cl)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 1/20 0.52
FGFR3 P22607 1/20 0.52
CDC7 O00311 2/20 0.41
CDK2 P24941 1/20 0.41
NPC1 O15118 6/20 0.40
RAB9A P51151 6/20 0.40
MAPT P10636 4/20 0.40
PKM P14618 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM4E B2RXH2 2/20 0.38
ALOX15 P16050 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PIK3CA P42336 2/20 0.38
MTOR P42345 1/20 0.38
NFKB1 P19838 1/20 0.37
CASP3 P42574 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
SENP7 Q9BQF6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6528572 0.84 FGFR2 (0.47) FGFR2FGFR3CDC7CDK2MAPT
SCHEMBL581207 0.81 NPC1 (0.41) FGFR2FGFR3NPC1RAB9AMAPT
SCHEMBL581004 0.78 DPP4 (0.40) FGFR2FGFR3NPC1RAB9AMAPT
SCHEMBL27930287 0.77 FGFR2 (0.54) FGFR2FGFR3NPC1RAB9AMAPT
SCHEMBL8744274 0.76 ALDH1A1 (0.46) FGFR2FGFR3NPC1RAB9AMAPT
SCHEMBL503736 0.75 CDK5 (0.53) CDC7CDK2NPC1RAB9AKDM4E
SCHEMBL581005 0.75 FGFR3 (0.43) FGFR2FGFR3NPC1RAB9AMAPT
SCHEMBL27795618 0.75 PKM (0.45) FGFR2FGFR3RAB9AMAPTPKM
SCHEMBL27761013 0.74 NPC1 (0.50) NPC1RAB9AMAPTPKMMEN1
SCHEMBL27542615 0.73 SMN1; SMN2 (0.67) NPC1MAPTMEN1KMT2AALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6881737-B2 Substituted triazinyl acrylamide derivatives and methods of use AMGEN INC. (US) 2005-04-19 US disclosed
US-6864255-B2 Substituted triazinyl amide derivatives and methods of use AMGEN INC. (US) 2005-03-08 US disclosed
EP-1390354-A1 TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS Amgen Inc. (US) 2004-02-25 EP disclosed
EP-1385833-A1 TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS Amgen Inc. (US) 2004-02-04 EP disclosed
US-20030139416-A1 Substituted triazinyl acrylamide derivatives and methods of use AMGEN INC. 2003-07-24 US disclosed
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use AMGEN INC. 2003-05-08 US disclosed
WO-2002083654-A1 TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS AMGEN INC. (US) 2002-10-24 WO disclosed
WO-2002083653-A1 TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS AMGEN INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139416-A1 Substituted triazinyl acrylamide derivatives and methods of use PKD1, PKD2, GLS FGFR2 3520/4885FGFR3 1523/4885CDC7 1701/4885
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use FLT4, FLT1, VEGFA FGFR2 1002/4885FGFR3 259/4885CDC7 3519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.